About Arbella

Arbella Therapeutics is an early stage biotechnology company focused on discovering and developing innovative small molecule oncology therapies to help patients with severe unmet medical needs.

Arbella was established in 2015 to develop best-in-class medicines to treat cancers for which current targeted therapies are ineffective or non-existent.

Our focus is on genetic mutation-driven targets, and our research is driven by our understanding of how mutation-driven cancers can evade or overcome current therapies.

Arbella also has the goal of making novel, innovative, and targeted therapies more affordable than is typically the case for new oncology treatments, and therefore more widely available.

Working together with scientists at several research institutions, Arbella’s team has developed a promising pipeline, with multiple compounds in discovery to preclinical stage.

Our internal Research and Development efforts are currently advancing in the course of 2021, and we are also working with international partners.